Rutherford Health - Agreement to provide services to NHS
RNS Number : 5430L
Rutherford Health PLC
13 January 2021

Rutherford Health PLC


Agreement to provide services to NHS


London, UK, 13 January, 2021: Rutherford Health plc (the "Company" or "Group" or "Rutherford Health") announces that Rutherford Cancer Care Limited, its wholly owned subsidiary, has entered into a framework agreement with NHS England under which it will provide cancer treatment and diagnostic imaging services to NHS Trusts and clinical commissioning groups.


The agreement is for a two-year period with an option to extend for a further two years on the agreement of both parties. Services will be provided at a pre-agreed set of prices.


Mike Moran, CEO of Rutherford Health plc, commented: "We are absolutely delighted to have signed this agreement with NHS England. We have been supplying radiotherapy and systemic anti-cancer therapy to NHS patients in England and Wales. This agreement streamlines the procurement process and enables NHS organisations in England to commission a range of services directly from us. It means we will provide our services more widely.

"I am particularly pleased to be supporting the fantastic work that the NHS is doing at this extremely challenging time. Providing these much-needed cancer treatments and diagnostic services in dedicated cancer treatment facilities will help relieve pressure on NHS hospitals".

Information communicated within this announcement is deemed to constitute inside information as stipulated under the UK Market Abuse Regulation. Upon the publication of this announcement, this inside information is now considered to be in the public domain.


The directors of Rutherford Health plc accept responsibility for the contents of this announcement.




Rutherford Health plc

Michael Moran, Chief Executive Officer

Tel: +44 (0) 16 3381 0661

Grant Thornton (Corporate Adviser)

Tel: +44 (0) 20 7383 5100

Colin Aaronson / Jamie Barklem

Media House International   

07788 414 856 or 0207 710 0020

Ramsay Smith



About Rutherford Health

Rutherford Health plc is the UK incorporated holding company of a group committed to providing innovative cancer care of the highest quality. The Group's oncology centres in the UK, named The Rutherford Cancer Centres, offer a comprehensive range of cancer treatments to patients including proton beam therapy ("PBT"), conventional radiotherapy, chemotherapy, immunotherapy, imaging and wellbeing services. The Company was founded in 2015 by Mike Moran and UK and international cancer experts, including Professor Karol Sikora, former head of the World Health Organisation's cancer programme.

The Rutherford Cancer Centres feature the most advanced technologies and Rutherford Health Plc has formed a partnership with IBA (Ion Beam Applications), the world's leading provider of proton beam therapy solutions and Philips, a leader in health technology.

All centres offer proton beam therapy to medically-insured private patients, self-paying patients and NHS patients where the Rutherford is commissioned to provide these services.

Follow the Rutherford Cancer Centres on twitter: @therutherford_c


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.